Trial site
Spitalul Clinic Dr. I. Cantacuzino
Bucharest, 020475, RomaniaEU-13 widening countryNot linked to an institution yet
- 15running trials
- 9closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 212 trials
- Phase 312 trials
- Status
- Completed9 trials
- Active, not recruiting7 trials
- Recruiting6 trials
- Not yet recruiting2 trials
- Lead sponsor
- Boehringer Ingelheim3 trials
- Takeda3 trials
- Hoffmann-La Roche2 trials
- Horizon Therapeutics Ireland Designated Activity Company2 trials
- Ipsen2 trials
- and 11 more
Running trials
Not yet recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181· Phase 2· Boehringer Ingelheim· Source
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615· Phase 2· Takeda· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239· Phase 2· Zura Bio Inc· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· Phase 2· Immunovant Sciences GmbH· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155· Phase 2· argenx· Source
Active, not recruiting
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus
2024-510584-37-00· Phase 2· Zenas Biopharma (USA) LLC· Source
Active, not recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950· Phase 2· Takeda· Source
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· Phase 2· Takeda· Source
Active, not recruiting
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803· Phase 3· AstraZeneca· Source
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842· Phase 3· Ipsen· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT06991114· Phase 2· Artiva Biotherapeutics, Inc.· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403· Phase 3· Ipsen· Source
Completed
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
NCT04781543· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580· Phase 2· Boehringer Ingelheim· Source
Completed
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
NCT05630820· Phase 3· GlaxoSmithKline· Source
Completed
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
NCT05377489· Phase 3· Grünenthal GmbH· Source
Recruiting
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
NCT05369052· Phase 3· MicuRx· Source
Completed
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics
of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
2023-509782-20-00· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source
Report an error